MedTrace Logo

Nemvaleukin Alfa Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Cutaneous or Mucosal Melanoma - ARTISTRY-6

NCT04830124 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 173

Last updated 2025-06-10

No results posted yet for this study

Summary

This study observes the antitumor activity, safety, tolerability, PK, and pharmacodynamics in patients with inoperable and/or metastatic melanoma

Conditions

Interventions

DRUG

Nemvaleukin Alfa Subcutaneous

Subcutaneous injection of nemvaleukin every 7 days

DRUG

Nemvaleukin Alfa Intravenous

Intravenous (IV) infusion over 30 minutes given daily for 5 consecutive days

DRUG

Nemvaleukin Alfa Intravenous Less Frequent Dosing

Intravenous (IV) infusion over 30 minutes twice every 21 days (Day 1 and Day 8 dosing of a 21 day cycle)

DRUG

Pembrolizumab

Cohort 4 only: 200mg IV pembrolizumab on Day 1 of a 21-day cycle

Sponsors & Collaborators

  • Mural Oncology, Inc

    lead INDUSTRY

Principal Investigators

  • Mural Oncology Medical Monitor · Mural Oncology

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-27
Primary Completion
2025-05-08
Completion
2025-05-08
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Canada
  • Italy
  • South Korea
  • Spain
  • Taiwan
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04830124 on ClinicalTrials.gov